Drug intelligence / Profile preview

Lu AA41178

Development stage: Preclinical
Lead developer: Lundbeck
Modality: Small Molecules
Administration: Subcutaneous

Overview

Lu AA41178 is a brain-penetrant, pan-selective Kv7 (KCNQ2–5) potassium channel opener developed by H. Lundbeck A/S. It acts as a potent activator of neuronal Kv7.2, Kv7.3, Kv7.4, and Kv7.5 channels, shifting their voltage-dependent activation threshold to more negative potentials. In preclinical studies, Lu AA41178 has demonstrated anticonvulsant, antipsychotic-like, and antidepressant-like efficacy in animal models of epilepsy, schizophrenia, and depression, without displaying inhibitory effects on cardiac Kv7.1 channels or GABAA receptors.

Targets

KCNQ2 (Potassium voltage-gated channel subfamily KQT member 2)KCNQ3 (Potassium voltage-gated channel subfamily Q member 3)KCNQ4 (Potassium channel subfamily KQT member 4)KCNQ5 (Potassium voltage-gated channel subfamily KQT member 5)

Beyond the preview

Go deeper on Lu AA41178.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lu AA41178.